LDN vs peptides for inflammation: what actually has evidence?

If you are managing a chronic inflammatory condition and searching for something that actually helps, two very different options keep coming up: low-dose naltrexone (LDN) and research peptides like KPV or BPC-157. They are often discussed in the same breath, as if they were interchangeable “anti-inflammatory” choices. They are not. They differ on the two things that matter most for a real decision: how strong the human evidence is, and how much is known about side effects. This page lays both out side by side, with every factual claim tied to a primary source, so you can compare them honestly rather than on marketing.

What is low-dose naltrexone (LDN), and how is it used for inflammation?

Naltrexone is not a new or exotic drug. It is a pure opioid-receptor antagonist that gained FDA approval back in the 1980s and 1990s, at a 50 mg daily dose, for opioid dependence and, later, alcohol use disorder (NCBI/SAMHSA treatment reference). “Low-dose naltrexone” refers to using a much smaller dose, typically around 1.5 to 4.5 mg, well below the approved 50 mg. At that low dose it is being studied for a different purpose entirely: a proposed anti-inflammatory and pain-modulating effect, thought to involve transient opioid-receptor blockade and effects on immune signaling.

Because naltrexone is a drug approved by the FDA, a licensed provider can prescribe it off-label at a low dose, and that is how LDN is used for inflammation. That does not mean LDN is proven for inflammation, or approved by the FDA for it; it is neither. It does mean it is used under a prescriber who can monitor it, and that it has been tested in small controlled human trials, which the peptides have not.

What is the human evidence for LDN in inflammatory conditions?

This is where honesty matters, because LDN is genuinely studied in people, but the results are limited and mixed rather than definitive.

In Crohn’s disease, a Cochrane systematic review pooled the controlled evidence and found very little of it: only two randomized studies with 46 participants total. Its conclusion is blunt: “there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of LDN used to treat patients with active Crohn’s disease,” with the evidence graded low quality, and the adult trial showing no statistically significant difference from placebo in clinical remission (Cochrane review, Parker et al.).

In fibromyalgia, the picture is similarly unsettled. A 2025 systematic review and meta-analysis of five randomized trials concluded that “LDN is considered to be effective in the treatment of fibromyalgia” with no serious adverse effects, but the same authors flagged “substantial heterogeneity among the included studies, moderate to high risk of bias and lesser number of studies with smaller sample sizes” and called for more trials (meta-analysis, PMC). And a well-conducted crossover randomized trial in about 50 fibromyalgia patients found the opposite of a win: it reported that the “outcome data did not indicate any clinically relevant analgesic efficacy of the LDN treatment” (Bruun-Plesner et al., PMC). So LDN’s human evidence is real, but small, mixed, and not yet conclusive: promising enough to study, not strong enough to call proven.

What is the evidence for research peptides in inflammation?

The peptides marketed for inflammation sit at an earlier stage of science. Their inflammation evidence is almost entirely preclinical: cell cultures and animal models, not human trials.

Take KPV, a three-amino-acid fragment of α-melanocyte-stimulating hormone. Its most-cited inflammation work is a study in which orally administered KPV reduced the severity of chemically induced colitis in mice and dampened inflammatory signaling in cell lines, with the authors framing it as a candidate worth studying, not an available therapy (Dalmasso et al., Gastroenterology; PMC). There is no completed human clinical trial of KPV for any inflammatory condition. BPC-157 is similar: a 2024 review describes its gastrointestinal research as conducted largely in rat models of conditions like colitis and anastomosis healing, again without a completed controlled human efficacy trial (Bajramagic et al., Pharmaceuticals; PMC). “Encouraging in mice” is a real and interesting result, but it is a reason to run a human trial, not a substitute for one. Our companion pages go deeper on the KPV inflammation research and on peptides and chronic conditions in 2026.

What side effects are known for LDN and for the peptides?

This is where the two options differ most in practice, because LDN has been given to people in controlled trials and the peptides largely have not.

LDN. In the Crohn’s disease trials, the Cochrane reviewers found “no statistically significant differences in withdrawals due to adverse events or specific adverse events including sleep disturbance, unusual dreams, headache, decreased appetite, nausea and fatigue,” and no serious adverse events, while cautioning that this rests on very small numbers of patients. The 2025 fibromyalgia meta-analysis found one consistent difference: “the incidence of vivid dreams (RR 2.41; 95% CI 1.77, 3.28) was significantly higher in treatment group as compared to placebo,” with no link to headache and no serious adverse effects reported. So the known side-effect picture for LDN is mild and dominated by sleep and dream changes, based on small trials.

The research peptides. For KPV there is no human safety data at all, because there are no human trials. For BPC-157, a 2025 review of the human literature found only three small published human studies and concluded that “due to the paucity of studies done in humans thus far, there is also limited data regarding safety and associated side effects”. The honest summary is not “the peptides are dangerous” but “nobody has measured it.”

LDN vs peptides for inflammation, side by side

The table condenses the whole comparison. It maps what each option is, its strongest evidence today, and what is known about side effects.

Two takeaways from that table. First, LDN and the peptides are not competing on equal footing: LDN has actual (if limited and mixed) human data, including side-effect data, while the peptides do not yet. Second, “LDN has more evidence” is not the same as “LDN is proven to work for you.” Both statements can be true, and a good clinician holds both at once.

The honest next step for a chronic inflammatory condition

If your real goal is to get a chronic inflammatory condition under control, the productive move is not to pit two under-evidenced options against each other and pick a winner from a forum thread. It is to bring the goal, not a specific molecule, to a licensed provider who can weigh what actually has evidence for your situation. For some people that conversation may reasonably include a trial of LDN, which a provider can prescribe and monitor; for others the right answer is an established, better-evidenced therapy or a specialist referral. If a peptide is on your mind, raise it in the same conversation, so it is weighed against your history and the evidence rather than on a claim the science does not yet support. That is the difference clinical supervision makes.

Status: BPC-157: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. KPV: Not FDA-approved. What these status terms mean.

Key takeaways

• LDN is a low, off-label dose of naltrexone, a drug approved by the FDA, prescribed by a licensed provider, though it is not approved for inflammation specifically.
• LDN’s human evidence is real but limited and mixed: a Cochrane review found insufficient evidence in Crohn’s disease, and fibromyalgia trials are split between a positive meta-analysis and a negative crossover trial.
• The research peptides (KPV, BPC-157) have inflammation evidence that is almost entirely preclinical: cells and animals, with no completed human efficacy trials.
• LDN’s measured side effects in small trials are mostly mild, with vivid dreams the clearest signal; the peptides’ side effects in people are largely unmeasured.
• The honest comparison is about evidence level, not “which is stronger,” and the best next step is bringing your goal to a licensed provider.